{"schemaVersion":"1.0","precedentGraphVersion":"RPG-0.6","answerAsOf":"2026-08-12","clusterCount":5,"memberEdgeCount":27,"clusters":[{"id":"precedent:july-2026-favorable-advice","slug":"july-2026-favorable-advice","peplystId":"peplyst:precedent:july-2026-favorable-advice:v1","title":"Favorable July 2026 PCAC advice","comparisonAxis":"committee_outcome","sharedFeature":"The committee gave each member a favorable advisory recommendation for possible 503A Bulks List inclusion.","transferLimit":"The shared vote does not establish equivalent evidence, safety, identity, FDA approval, final-list status, or eventual FDA action.","memberSlugs":["bpc-157","kpv","tb-500","mots-c","epitalon","semax"],"memberNames":["BPC-157","KPV","TB-500","MOTS-c","Epitalon","Semax"],"sourceUrls":["https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","https://www.fda.gov/media/193343/download","https://www.fda.gov/media/193346/download","https://www.fda.gov/media/193349/download","https://www.fda.gov/media/193347/download","https://www.fda.gov/media/193345/download","https://www.fda.gov/media/193348/download"],"confidence":94,"answerAsOf":"2026-08-12","reviewGate":"human_review_required_for_substantive_change"},{"id":"precedent:july-2026-reviewed-cohort","slug":"july-2026-reviewed-cohort","peplystId":"peplyst:precedent:july-2026-reviewed-cohort:v1","title":"Same review cycle, divergent outcome","comparisonAxis":"committee_outcome","sharedFeature":"All seven members were evaluated during the July 2026 PCAC peptide review cycle.","transferLimit":"Shared timing and process do not erase Emideltide's unfavorable committee outcome or make the compounds clinically interchangeable.","memberSlugs":["bpc-157","kpv","tb-500","mots-c","epitalon","semax","emideltide"],"memberNames":["BPC-157","KPV","TB-500","MOTS-c","Epitalon","Semax","Emideltide / DSIP"],"sourceUrls":["https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","https://www.fda.gov/media/193343/download","https://www.fda.gov/media/193346/download","https://www.fda.gov/media/193349/download","https://www.fda.gov/media/193347/download","https://www.fda.gov/media/193345/download","https://www.fda.gov/media/193348/download","https://www.fda.gov/media/193344/download"],"confidence":94,"answerAsOf":"2026-08-12","reviewGate":"human_review_required_for_substantive_change"},{"id":"precedent:no-identified-human-exposure","slug":"no-identified-human-exposure","peplystId":"peplyst:precedent:no-identified-human-exposure:v1","title":"No human exposure identified in the tracked FDA record","comparisonAxis":"human_evidence_boundary","sharedFeature":"FDA reported no identified human exposure data in the tracked context for these members.","transferLimit":"A shared absence of human exposure data does not establish shared mechanism, efficacy, risk, safety, dose, route, or legal status.","memberSlugs":["kpv","tb-500","mots-c","dihexa-acetate","peg-mgf"],"memberNames":["KPV","TB-500","MOTS-c","Dihexa acetate","PEG-MGF"],"sourceUrls":["https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","https://www.fda.gov/media/193346/download","https://www.fda.gov/media/193349/download","https://www.fda.gov/media/193347/download","https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"],"confidence":94,"answerAsOf":"2026-08-12","reviewGate":"human_review_required_for_substantive_change"},{"id":"precedent:limited-human-record","slug":"limited-human-record","peplystId":"peplyst:precedent:limited-human-record:v1","title":"Limited human record, not established benefit","comparisonAxis":"human_evidence_boundary","sharedFeature":"The tracked FDA record includes limited or inconsistent human information rather than established clinical benefit.","transferLimit":"The amount, design, indication, formulation, route, and quality of human information differ by member; evidence cannot be pooled across the cluster.","memberSlugs":["bpc-157","epitalon","semax","emideltide"],"memberNames":["BPC-157","Epitalon","Semax","Emideltide / DSIP"],"sourceUrls":["https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026","https://www.fda.gov/media/193343/download","https://www.fda.gov/media/193345/download","https://www.fda.gov/media/193348/download","https://www.fda.gov/media/193344/download"],"confidence":94,"answerAsOf":"2026-08-12","reviewGate":"human_review_required_for_substantive_change"},{"id":"precedent:future-pcac-cohort","slug":"future-pcac-cohort","peplystId":"peplyst:precedent:future-pcac-cohort:v1","title":"Future PCAC review cohort","comparisonAxis":"process_stage","sharedFeature":"FDA announced future PCAC consideration; the meeting date and full compound-specific briefing record remain pending.","transferLimit":"Being in the same future-review cohort predicts neither committee advice nor final FDA action and does not establish equivalence among members.","memberSlugs":["ll-37","ghk-cu","dihexa-acetate","melanotan-ii","peg-mgf"],"memberNames":["LL-37","GHK-Cu","Dihexa acetate","Melanotan II","PEG-MGF"],"sourceUrls":["https://www.fda.gov/advisory-committees/pharmacy-compounding-advisory-committee/meeting-pharmacy-compounding-advisory-committee"],"confidence":94,"answerAsOf":"2026-08-12","reviewGate":"human_review_required_for_substantive_change"}]}